Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus GARAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus GARAMYCIN.
BETHKIS vs GARAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, leading to bacterial cell death.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
Gentamicin 3-5 mg/kg/day IV or IM in 3 divided doses every 8 hours for serious infections; may use once-daily dosing (5 mg/kg IV every 24 hours) for certain indications.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 40-50 hours in anuria).
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<2%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic